Theranostics · 2018 · 66 citations · 50 references
Life SciencesNeurologyNeuroscienceClinical NeuroscienceMetabolomicsNeurodegenerationBiomarkers Of NeurodegenerationCerebrospinal Fluid BiomarkersClinical MetabolomicsMultiple SclerosisNeurodegenerative DiseasesNeurodegenerative DisordersBiomarkersCsf-to-blood Biomarker RatiosDisease Progression PhenotypingEarly DiagnosisLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisMultiplexed ImmunoassaysNeurological Disease Biomarkers
Molecular networks in neurological diseases are complex. Despite this fact, contemporary biomarkers are in most cases interpreted in isolation, leading to a significant loss of information and power. We present an analytical approach to scrutinize and combine information from biomarkers originating from multiple sources with the aim of discovering a condensed set of biomarkers that in combination could distinguish the progressive degenerative phenotype of multiple sclerosis (SPMS) from the relapsing-remitting phenotype (RRMS). Methods: Clinical and magnetic resonance imaging (MRI) data were integrated with data from protein and metabolite measurements of cerebrospinal fluid, and a method was developed to sift through all the variables to establish a small set of highly informative measurements. This prospective study included 16 SPMS patients, 30 RRMS patients and 10 controls. Protein concentrations were quantitated with multiplexed fluorescent bead-based immunoassays and ELISA. The metabolome was recorded using liquid chromatography-mass spectrometry. Clinical follow-up data of the SPMS patients were used to assess disease progression and development of disability. Results: Eleven variables were in combination able to distinguish SPMS from RRMS patients with high confidence superior to any single measurement. The identified variables consisted of three MRI variables: the size of the spinal cord and the third ventricle and the total number of T1 hypointense lesions; six proteins: galectin-9, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor alpha (TGF-), tumor necrosis factor alpha (TNF-), soluble CD40L (sCD40L) and platelet-derived growth factor AA (PDGF-AA); and two metabolites: 20-dihydrocortisol (20-DHF) and indolepyruvate. The proteins myelin basic protein (MBP) and macrophage-derived chemokine (MDC), as well as the metabolites 20-DHF and 5,6-dihydroxyprostaglandin F1a (5,6-DH-PGF1), were identified as potential biomarkers of disability progression. Conclusion: Our study demonstrates, in a limited but well-defined and data-rich cohort, the importance and value of combining multiple biomarkers to aid diagnostics and track disease progression.
50
R: A Language and Environment for Statistical Computing
R Core Team · 2000 · 353K citations · Full text
Natural Sciences, Computer Science, Statistical Computing +10
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Xavier Robin, Natacha Turck, Alexandre Hainard et al. · BMC Bioinformatics · 2011 · 14K citations · Full text
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology · 2011 · 9.8K citations · Full text
Medicine, Neurology, Neuroscience +10
New Multiple Sclerosis Phenotypic Classification
Fred Lublin · European Neurology · 2014 · 4.3K citations
HMDB: the Human Metabolome Database
David S. Wishart, Dorit Tzur, Craig Knox et al. · Nucleic Acids Research · 2007 · 3.3K citations · Full text